Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of darvadstrocel for complex perianal fistula in pediatric Crohn's disease
MOH_2021-04-21_009673Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Nov 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of darvadstrocel in Crohn's disease, sponsored by Takeda. Primary endpoint: Combined remission at Week 24. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
darvadstrocel
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2021-04-21_009673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-21_009673.